Your session is about to expire
← Back to Search
Pembrolizumab Combination Therapy for Non-Small Cell Lung Cancer
Study Summary
This trial is looking at the efficacy and safety of two different drugs in combination with pembrolizumab for people with NSCLC who have been treated with anti-PD-L1 therapy before.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You had a very bad allergic reaction to a type of medication called monoclonal antibodies, including pembrolizumab.I had major surgery less than 3 weeks ago.You have taken part in Substudies 1 or 2.My lung cancer is confirmed to be at stage IV.I haven't had cancer treatment in the last 4 weeks or still have side effects.I have a history of Hepatitis B or active Hepatitis C.My lung cancer is non-squamous and I can't have targeted therapy.My organs are functioning well enough for treatment.I stopped immunotherapy due to a severe side effect.I am not pregnant or breastfeeding and either cannot become pregnant or will use contraception.I have an autoimmune disease treated with medication in the last 2 years.My cancer has worsened despite treatment with a specific immune therapy.I am a male and agree to use contraception and not donate sperm for 120 days after treatment.I have serious heart problems, such as recent heart attacks or severe heart failure.I have an immune system disorder or have been on high-dose steroids or other immune-weakening medicines recently.I am currently being treated for an infection.I have been diagnosed with HIV.I have received an organ or tissue transplant from another person.I have another cancer that is growing or was treated in the last 2 years.My cancer has worsened despite having platinum-based chemotherapy.I have not received any live vaccines other than approved COVID-19 vaccines in the last 30 days.I can provide a recent or archived sample of my tumor for testing.I've had lung radiation over 30 Gray in the last 6 months.I have had or currently have lung inflammation treated with steroids.I have been diagnosed with small cell lung cancer.I have cancer that has spread to my brain or spinal cord.
- Group 1: Boserolimab + Pembrolizumab
- Group 2: Pembrolizumab + MK-4830
- Group 3: Pembrolizumab + MK-0482
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What other medical research has been conducted with Pembrolizumab?
"Pembrolizumab was first studied in 2004 at the Clinical Addictions Research Laboratory. Since then, there have been 1010 completed trials and 1114 active studies recruiting patients. Many of these are based in Lexington, Kentucky."
Are investigators still looking for new participants for this experiment?
"No, this study is not currently enrolling patients. The trial was initially posted on January 21st, 2020 and the most recent edit was made on October 31st, 2022. There are 2508 other trials that may be recruiting at this time."
Could you tell me how many different hospitals are testing this new medication?
"There are 18 clinical trial sites running this particular study, including the University of Kentucky Markey Cancer Center (Site 0019) in Lexington, Laura and Isaac Perlmutter Cancer Center at NYU Langone Health (Site 0034) in New york, and University of California San Francisco (Site 0007) in Washington. Other locations include:"
What are some conditions that Pembrolizumab has been shown to be effective for?
"Pembrolizumab is an effective treatment for unresectable melanoma, microsatellite instability high, and catarrh."
Has Pembrolizumab been cleared by the FDA?
"Pembrolizumab falls into the category of a Phase 2 trial medication, so there is some evidence backing its safety. However, because it is still in clinical trials there is no data to support its efficacy."
Share this study with friends
Copy Link
Messenger